---
title: "Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: References"
description: "Reference list for the formulary evidence report on Zipalertinib (CLN-081, TAS6417) in EGFR exon 20 insertion-mutated non-small-cell lung cancer. 74 cited documents."
canonical: "https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: References

<a id="references"></a>

## 5 References

1. [Aggarwal and Liu (2023)](https://pubmed.ncbi.nlm.nih.gov/37487151/)
2. [Bazhenova et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34818606/)
3. [Behera et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38827378/)
4. [Burnett et al. (2021)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0247620)
5. [Canada’s Drug Agency (2025)](https://www.ncbi.nlm.nih.gov/books/NBK612158/table/t01/)
6. [Cao et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38990458/)
7. [ClinicalTrials.gov NCT07128199](https://clinicaltrials.gov/study/NCT07128199)
8. [Cullinan Therapeutics](https://cullinantherapeutics.com/science/pipeline/)
9. [Cullinan Therapeutics (2022)](https://investors.cullinantherapeutics.com/node/7366/pdf)
10. [Cullinan Therapeutics annual report (2026)](https://materials.proxyvote.com/Approved/230031/20260420/AR_632667.PDF)
11. [Cullinan Therapeutics ASCO oral presentation (2022)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN081-ASCO-Oral-Presentation-CLN-081.pdf)
12. [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)
13. [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)
14. [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf)
15. [Dabbah et al. (2026)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1812440/full)
16. [Dempke et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12838662/)
17. [Dixit and Das (2025)](https://pubmed.ncbi.nlm.nih.gov/41099528/)
18. [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)
19. [FDA (2018)](https://www.fda.gov/media/71195/download)
20. [FDA (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications)
21. [FDA (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20)
22. [Hamada et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37666482/)
23. [Hasako et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29748209/)
24. [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)
25. [Heymach et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39957151/)
26. [Horn et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8474204/)
27. [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html)
28. [Jänne et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39879577/)
29. [Journal of Clinical Oncology (2026)](https://ascopubs.org/doi/abs/10.1200/JCO-26-01931?af=R)
30. [Kagawa et al. (2023)](https://www.sciencedirect.com/science/article/pii/S2666364323000012)
31. [Kwon et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35621011/)
32. [Lau et al. (2026)](https://link.springer.com/article/10.1007/s40265-026-02329-7)
33. [Lin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8851244/)
34. [Lin et al. (2025)](https://academic.oup.com/oncolo/article-pdf/30/5/oyaf067/63126928/oyaf067.pdf)
35. [MedKoo Biosciences](https://www.medkoo.com/products/34604)
36. [MedKoo Biosciences safety data sheet (2022)](https://www.medkoo.com/uploads/product/Zipalertinib/safety/SDS-Zipalertinib.pdf)
37. [Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/cancer-care/clinical-trials/24-026)
38. [Miyamura et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12452814/)
39. [National Cancer Institute NCI-2023-10904](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10904)
40. [NICE TA1158 (2026)](https://www.nice.org.uk/guidance/ta1158)
41. [Ou et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36738930/)
42. [Ou et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37744306/)
43. [Oxnard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3549533/)
44. [Park et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8791812/)
45. [Paz-Ares et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41671629/)
46. [Piotrowska and Yu (2026)](https://pubmed.ncbi.nlm.nih.gov/41406409/)
47. [Piotrowska et al. (2019)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-001-WCLC-Poster-2019-08-30.pdf)
48. [Piotrowska et al. (2021)](https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9077)
49. [Piotrowska et al. (2023)](https://cullinantherapeutics.com/publications/safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patients-with-non-small-cell-lung-cancer-harboring-epidermal-growth-factor-receptor-exon-20-insertions-2023-jco/)
50. [Piotrowska et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40450572/)
51. [Puri et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02822)
52. [Riess et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6764748/)
53. [Taiho Oncology ASCO 2025 REZILIENT1 results announcement (2025)](https://www.taihooncology.com/us/news/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology-to-present-positive-results-from-pivotal-phase-2b-rezilient1-trial-of-zipalertinib-at-asco-2025/)
54. [Taiho Oncology ESMO Congress 2025 active brain metastases announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-in-patients-with-nsclc-with-egfr-mutations-and-active-brain-metastases-at-the-esmo-congress-2025/)
55. [Taiho Oncology expanded access policy](https://www.taihooncology.com/us/science/expanded-access/)
56. [Taiho Oncology IASLC 2025 World Conference on Lung Cancer announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer/)
57. [Taiho Oncology new drug application acceptance announcement (2026)](https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/)
58. [Taiho Oncology REZILIENT1 Journal of Clinical Oncology publication announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology/)
59. [Taiho Oncology REZILIENT1 phase 2b primary endpoint announcement (2025)](https://www.taihooncology.com/us/news/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy/)
60. [Taiho Oncology REZILIENT3 presidential symposium announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/)
61. [Taiho Oncology REZILIENT3 primary endpoint announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-of-progression-free-survival-in-planned-interim-analysis-of-phase-3-rezilient3-trial-in-first-line-egfr-exon-20-insertion-mutation-non-small-cell-lung-cancer/)
62. [Taiho Oncology rolling new drug application submission announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-e/)
63. [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)
64. [Udagawa et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6872223/)
65. [Udagawa et al. (2025)](https://www.sciencedirect.com/science/article/pii/S1556086425012109)
66. [Vadagam et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38269536/)
67. [Vidal et al. (2024)](https://doi.org/10.1200/OP.23.00253)
68. [Viteri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9892822/)
69. [Waterhouse et al. (2026)](https://link.springer.com/article/10.1186/s12890-026-04334-8)
70. [Xie et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40337604/)
71. [Yang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40923280/)
72. [Yao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41406405/)
73. [Zhou et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37870976/)
74. [Zhou et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42212913/)

## Related pages
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Product information and disease description](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical evidence](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
